Diabetes Mellitus, Insulin-Dependent
Conditions
Keywords
Diabetes,Insulin-Dependent, pediatric,rapid acting injection
Brief summary
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
Interventions
DRUGInsulin glulisine
Subcutaneous injection
DRUGinsulin lispro
Subcutaneous injection
DRUGinsulin glargine
Subcutaneous injection once daily
DRUGNPH insulin
subcutaneous injection twice daily
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Girls/boys, 4-17 years, inclusive; * Girls not yet of childbearing potential or, if sexually active, agree to use reliable medically accepted contraceptive measure during study; * Type 1 diabetes mellitus established in medical history: for example, but not limited to, clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss, ketonuria, ketoacidosis); or glutamic acid decarboxylase (GAD) antibody indicative of type 1 diabetes measured at any time before study; or requiring continuous insulin therapy from time of diagnosis; * Onset of diabetes at least 1 year prior to visit 1 (V1) of study; * Uninterrupted insulin therapy for at least 1 year before V1 of study; * At V1, on stable insulin regimen of either NPH or insulin glargine as basal insulin and willing to have multiple daily injections of insulin; * Glycated hemoglobin at V1 between ≥ 6.0 and ≤11.0 %; * Ability/willingness to do blood glucose monitoring using sponsor-provided glucometer and subject diary.
Exclusion criteria
* Active proliferative diabetic retinopathy, defined by application of focal or panretinal photocoagulation or vitrectomy, 6 months before V1, or any other unstable/rapidly progressing retinopathy requiring surgical treatment (including laser photocoagulation) during study; * Diabetes other than type 1 diabetes mellitus; * Pregnancy (positive pregnancy blood test at V1) or breastfeeding; * Pancreatectomized subjects; * Subjects who have had pancreas and/or islet cell transplants; * Treatment with any anti-diabetic oral agent at any time from diabetes diagnosis; * Treatment with systemic corticosteroids in last month before V1; * Subjects on pump therapy during last 2 months before V1; * Subjects requiring excessively high doses of insulin (resistant patients), for example, but not limited to, subjects receiving over 150 IU per day; * Likelihood of needing treatment during study period with drugs not permitted by protocol * Treatment with any investigational drug in last month before V1; * History of primary seizure disorders; * History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic ketoacidosis leading to hospitalization, or to care in emergency ward, 3 months prior to V1; * History of hypoglycemia unawareness; * History of hypersensitivity to insulin or insulin analogs or any of the excipients in insulin glulisine formulation or any of the excipients in other study insulin preparations formulations; * Clinically relevant hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of protocol or interpretation of study results difficult and would, in the opinion of the investigator, preclude safe participation of subject in protocol; * History of cardiac abnormalities and/or cardiovascular disorders; * History of drug/alcohol abuse; * Impaired hepatic function shown by, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than twice the normal upper limit for age at V1; * Impaired renal function shown by, but not limited to, serum creatinine greater than 1.5 times upper limit for age at V1; * Non fasting triglyceride level of \>500 mg/dL (5.7 mmol/L) at V1; * Parent/legally authorized representative unable to understand nature, scope, possible consequences of study; * Parent/legally authorized representative unable to read/write; * Subjects unlikely to comply with protocol, e.g. inability/unwillingness to participate in adequate training, uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing study; * Children/relatives of employee of sponsor or of sponsor representatives; * Children or relatives of investigator, any sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conduct of protocol; * Subjects who have previously been treated with insulin glulisine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint | week 26 or last observed treatment |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in GHb at weeks 12 and 26 | weeks 12 and 26 |
| Change from Baseline in Self-monitored glucose parameters | weeks 4, 12, 18, 26, and endpoint; |
| Incidence of Symptomatic hypoglycemia | first dose of study up to last dose |
| Change from Baseline in basal insulin dose | week 4, 12, 18, 26, and endpoint; |
Countries
United States
Outcome results
None listed